129 related articles for article (PubMed ID: 35716193)
41. [Expanded curettage and bone cement filling combined with internal fixation for the treatment of Campanacci III giant cell tumour of knee joint].
Song Y; Li CF; Shi XT; Cheng YQ; Suo HQ; Liu JG
Zhongguo Gu Shang; 2019 Apr; 32(4):372-376. PubMed ID: 31027417
[TBL] [Abstract][Full Text] [Related]
42. Curettage as first surgery for bone giant cell tumor : adequate surgery is more important than oncology training or surgical management by high volume specialized teams.
Tsukamoto S; Mavrogenis AF; Tanzi P; Leone G; Akahane M; Tanaka Y; Errani C
Eur J Orthop Surg Traumatol; 2020 Jan; 30(1):3-9. PubMed ID: 31520122
[TBL] [Abstract][Full Text] [Related]
43. Segmental excision versus intralesional curettage with adjuvant therapy for giant cell tumour of bone.
Yacob O; Umer M; Gul M; Qadir I
J Orthop Surg (Hong Kong); 2016 Apr; 24(1):88-91. PubMed ID: 27122520
[TBL] [Abstract][Full Text] [Related]
44. Re-operation results in osteoarthritic change of knee joints in patients with giant cell tumor of bone.
Suzuki Y; Nishida Y; Yamada Y; Tsukushi S; Sugiura H; Nakashima H; Ishiguro N
Knee; 2007 Oct; 14(5):369-74. PubMed ID: 17601737
[TBL] [Abstract][Full Text] [Related]
45. Giant cell tumor of extremities, surgical treatment and local adjuvants: which is the most effective?
Colangeli S; Del Chiaro A; Andreani L; D'Arienzo A; Parchi P; Capanna R
J Biol Regul Homeost Agents; 2020; 34(5 Suppl. 1):57-62. IORS Special Issue on Orthopedics. PubMed ID: 33739006
[TBL] [Abstract][Full Text] [Related]
46. Late development of malignant fibrous histiocytoma at the site of a giant cell tumour 38 years after initial surgery.
Muramatsu K; Ihara K; Miyoshi T; Kawakami Y; Nakashima D; Taguchi T
Acta Orthop Belg; 2012 Apr; 78(2):279-84. PubMed ID: 22697003
[TBL] [Abstract][Full Text] [Related]
47. Recurrence Rates and Risk Factors for Primary Giant Cell Tumors around the Knee: A Multicentre Retrospective Study in China.
Hu P; Zhao L; Zhang H; Yu X; Wang Z; Ye Z; Wu S; Guo S; Zhang G; Wang J; Ning X; Hu Y; Zhang Y
Sci Rep; 2016 Nov; 6():36332. PubMed ID: 27827384
[TBL] [Abstract][Full Text] [Related]
48. Giant-cell tumours with fracture at diagnosis. Curettage and acrylic cementing in ten cases.
Dreinhöfer KE; Rydholm A; Bauer HC; Kreicbergs A
J Bone Joint Surg Br; 1995 Mar; 77(2):189-93. PubMed ID: 7706330
[TBL] [Abstract][Full Text] [Related]
49. Current status of bone cementing and bone grafting for giant cell tumour of bone: a systemic review.
Vaishya R; Pokhrel A; Agarwal AK; Vijay V
Ann R Coll Surg Engl; 2019 Feb; 101(2):79-85. PubMed ID: 30688529
[TBL] [Abstract][Full Text] [Related]
50. Pictorial review: giant cell tumours of bone.
Lee MJ; Sallomi DF; Munk PL; Janzen DL; Connell DG; O'Connell JX; Logan PM; Masri BA
Clin Radiol; 1998 Jul; 53(7):481-9. PubMed ID: 9714386
[TBL] [Abstract][Full Text] [Related]
51. Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone?
Gaston CL; Bhumbra R; Watanuki M; Abudu AT; Carter SR; Jeys LM; Tillman RM; Grimer RJ
J Bone Joint Surg Br; 2011 Dec; 93(12):1665-9. PubMed ID: 22161931
[TBL] [Abstract][Full Text] [Related]
52. Clinical Significance of Preoperative CT and MR Imaging Findings in the Prediction of Postoperative Recurrence of Spinal Giant Cell Tumor of Bone.
Wang QZ; Zhang EL; Xing XY; Su MY; Lang N
Orthop Surg; 2021 Dec; 13(8):2405-2416. PubMed ID: 34841660
[TBL] [Abstract][Full Text] [Related]
53. Giant cell tumour of the femur in a 9-year-old girl, resulting in severe leg length discrepancy.
Oba M; Inaba Y; Machida J; Saito T
BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 27001598
[TBL] [Abstract][Full Text] [Related]
54. Recurrence of giant-cell tumors of the long bones after curettage and packing with cement.
O'Donnell RJ; Springfield DS; Motwani HK; Ready JE; Gebhardt MC; Mankin HJ
J Bone Joint Surg Am; 1994 Dec; 76(12):1827-33. PubMed ID: 7989388
[TBL] [Abstract][Full Text] [Related]
55. Higher local recurrence rates after intralesional surgery for giant cell tumor of the proximal femur compared to other sites.
Errani C; Tsukamoto S; Leone G; Akahane M; Cevolani L; Tanzi P; Kido A; Honoki K; Tanaka Y; Donati DM
Eur J Orthop Surg Traumatol; 2017 Aug; 27(6):813-819. PubMed ID: 28589498
[TBL] [Abstract][Full Text] [Related]
56. Inactivated autograft-prosthesis composite has a role for grade III giant cell tumor of bone around the knee.
Xu S; Yu X; Xu M; Fu Z
BMC Musculoskelet Disord; 2013 Nov; 14():319. PubMed ID: 24209887
[TBL] [Abstract][Full Text] [Related]
57. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
[TBL] [Abstract][Full Text] [Related]
58. Treatment of giant-cell tumors of long bones with curettage and bone-grafting.
Blackley HR; Wunder JS; Davis AM; White LM; Kandel R; Bell RS
J Bone Joint Surg Am; 1999 Jun; 81(6):811-20. PubMed ID: 10391546
[TBL] [Abstract][Full Text] [Related]
59. [Clinical observation of surgical management for recurrent giant cell tumor of bone].
Kong Q; Yang J; Xing R; Tu C; Zhou Y; Zhang H; Duan H
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2013 Jan; 27(1):36-40. PubMed ID: 23427489
[TBL] [Abstract][Full Text] [Related]
60. Functional results after giant cell tumor operation near knee joint and the cement radiolucent zone as indicator of recurrence.
Kafchitsas K; Habermann B; Proschek D; Kurth A; Eberhardt C
Anticancer Res; 2010 Sep; 30(9):3795-9. PubMed ID: 20944172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
